Cluster of differentiation 45 activation is crucial in interleukin‑10‑dependent tumor‑associated dendritic cell differentiation

Cheng,Da‑En; Tsai,Ying‑Ming; Hsu,Ya‑Ling; Hou,Ming‑Feng; Tsai,Eing‑Mei; Wang,Jaw‑Yuan; Kan,Jung‑Yu; Kuo,Po‑Lin

doi:10.3892/ol.2014.2161

Cluster of differentiation 45 activation is crucial in interleukin‑10‑dependent tumor‑associated dendritic cell differentiation

Authors:
- Da‑En Cheng
- Ying‑Ming Tsai
- Ya‑Ling Hsu
- Ming‑Feng Hou
- Eing‑Mei Tsai
- Jaw‑Yuan Wang
- Jung‑Yu Kan
- Po‑Lin Kuo
View Affiliations

Affiliations: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Division of Pulmonary and Critical Care Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C., Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
Published online on: May 19, 2014 https://doi.org/10.3892/ol.2014.2161
Pages: 620-626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor‑associated dendritic cells (TADCs) are important in tumor immune surveillance, and it has been reported that the secretion of interleukin (IL)‑10 by cancer cells is a major factor involved in the induction of TADCs in the tumor microenvironment. In the present study, IL‑10 was found to activate cluster of differentiation (CD)45 protein tyrosine phosphatase (PTPase), inducing a TADC‑like phenomenon. The PTPase inhibitor, phenylarsine oxide, and a CD45 inhibitor reversed the IL‑10‑induced impaired differentiation of the DCs, and also reversed the induction of the TADCs by A549, MDA‑MB‑231 and SW480 conditioned media, which thus represents a novel therapy to reduce immune surveillance in the tumor microenvironment. The present study is the first to identify that CD45 is involved in IL‑10‑activated signaling in myeloid lineage cells.

View Figures

View References

1	Steinman RM: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:271–296. 1991.
2	Nestle FO, Burg G, Fäh J, Wrone-Smith T and Nickoloff BJ: Human sunlight-induced basal-cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am J Pathol. 150:641–651. 1997.
3	Watkins SK, Zhu Z, Riboldi E, et al: FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest. 121:1361–1372. 2011.
4	Kuo CH, Chen KF, Chou SH, et al: Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway. Carcinogenesis. 34:2600–2609. 2013.
5	Kuo PL, Huang MS, Cheng DE, Hung JY, Yang CJ and Chou SH: Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem. 287:9753–9764. 2012.
6	Hsu YL, Huang MS, Cheng DE, et al: Lung tumor-associated dendritic cell-derived amphiregulin increased cancer progression. J Immunol. 187:1733–1744. 2011.
7	Han Y, Chen Z, Yang Y, et al: Human CD14⁺ CTLA-4⁺ regulatory dendritic cells suppress T cell response via cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology. 59:567–579. 2013.
8	Lindenberg JJ, Oosterhoff D, Sombroek CC, et al: IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. PloS One. 8:e702372013.
9	Kuo PL, Hung JY, Huang SK, et al: Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J Immunol. 186:1521–1530. 2011.
10	Lindenberg JJ, van de Ven R, Lougheed SM, et al: Functional characterization of a STAT3-dependent dendritic cell-derived CD14 cell population arising upon IL-10-driven maturation. Oncoimmunology. 2:e238372013.
11	Donnelly RP, Dickensheets H and Finbloom DS: The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res. 19:563–573. 1999.
12	Sato K, Nagayama H, Tadokoro K, Juji T and Takahashi TA: Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol. 162:3865–3872. 1999.
13	Staples KJ, Smallie T, Williams LM, et al: IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. J Immunol. 178:4779–4785. 2007.
14	Niemand C, Nimmesgern A, Haan S, et al: Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol. 170:3263–3272. 2003.
15	Porcu M, Kleppe M, Gianfelici V, et al: Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood. 119:4476–4479. 2012.
16	Xu D and Qu CK: Protein tyrosine phosphatases in the JAK/STAT pathway. Front Biosci. 13:4925–4932. 2008.
17	Irie-Sasaki J, Sasaki T, Matsumoto W, et al: CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature. 409:349–354. 2001.
18	McFarland EC, Hurley TR, Pingel JT, Sefton BM, Shaw A and Thomas ML: Correlation between Src family member regulation by the protein-tyrosine-phosphatase CD45 and transmembrane signaling through the T-cell receptor. Proc Natl Acad Sci USA. 90:1402–1406. 1993.
19	Hurley TR, Hyman R and Sefton BM: Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn, and c-src tyrosine protein kinases. Mol Cell Biol. 13:1651–1656. 1993.
20	Bataille R, Robillard N, Pellat-Deceunynck C and Amiot M: A cellular model for myeloma cell growth and maturation based on an intraclonal CD45 hierarchy. Immunol Rev. 194:105–111. 2003.
21	Fulcher JA, Chang MH, Wang S, et al: Galectin-1 co-clusters CD43/CD45 on dendritic cells and induces cell activation and migration through Syk and protein kinase C signaling. J Biol Chem. 284:26860–26870. 2009.
22	Descamps G, Pellat-Deceunynck C, Szpak Y, Bataille R, Robillard N and Amiot M: The magnitude of Akt/phosphatidylinositol 3′-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol. 173:4953–4959. 2004.
23	Ishikawa H, Mahmoud MS, Fujii R, Abroun S and Kawano MM: Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma. Leuk Lymphoma. 39:51–55. 2000.
24	Timmerman JM and Levy R: Dendritic cell vaccines for cancer immunotherapy. Ann Rev Med. 50:507–529. 1999.
25	Théry C and Amigorena S: The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol. 13:45–51. 2001.
26	Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 3:991–998. 2002.
27	Almand B, Resser JR, Lindman B, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 6:1755–1766. 2000.
28	Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 2:1096–1103. 1996.
29	Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J and Enk AH: Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood. 93:1634–1642. 1999.
30	Qin Z, Noffz G, Mohaupt M and Blankenstein T: Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol. 159:770–776. 1997.
31	Gregori S, Tomasoni D, Pacciani V, et al: Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 116:935–944. 2010.
32	Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS and Tisch R: Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood. 104:1100–1109. 2004.
33	Song GY, Chung CS, Schwacha MG, Jarrar D, Chaudry IH and Ayala A: Splenic immune suppression in sepsis: A role for IL-10-induced changes in P38 MAPK signaling. J Surg Res. 83:36–43. 1999.
34	Arimura Y, Ogimoto M, Mitomo K, et al: CD45 is required for CD40-induced inhibition of DNA synthesis and regulation of c-Jun NH2-terminal kinase and p38 in BAL-17 B cells. J Biol Chem. 276:8550–8556. 2001.
35	Hayes AL, Smith C, Foxwell BM and Brennan FM: CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor-kappaB-independent. J Biol Chem. 274:33455–33461. 1999.
36	Hoffman JF, Linderman JJ and Omann GM: Receptor up-regulation, internalization, and interconverting receptor states Critical components of a quantitative description of N-formyl peptide-receptor dynamics in the neutrophil. J Biol Chem. 271:18394–18404. 1996.
37	Kutsumi H, Kawai K, Johnston RB Jr and Rokutan K: Evidence for participation of vicinal dithiols in the activation sequence of the respiratory burst of human neutrophils. Blood. 85:2559–2569. 1995.
38	Planat V, Tronchere H, Record M, Ribbes G and Chap H: Involvement of vicinal dithiols in differential regulation of fMLP and phorbol ester-activated phospholipase D in stimulated human neutrophils. Biochem Biophys Res Commun. 218:847–853. 1996.
39	Dowling P and Clynes M: Conditioned media from cell lines: a complementary model to clinical specimens for the discovery of disease-specific biomarkers. Proteomics. 11:794–804. 2011.
40	Bailey C, Negus R, Morris A, et al: Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis. 24:121–130. 2007.
41	Ghosh D, Yu H, Tan XF, et al: Identification of key players for colorectal cancer metastasis by iTRAQ quantitative proteomics profiling of isogenic SW480 and SW620 cell lines. J Proteome Res. 10:4373–4387. 2011.
42	Ma C, Rong Y, Radiloff DR, et al: Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev. 22:308–321. 2008.
43	Coffey RJ Jr, Shipley GD and Moses HL: Production of transforming growth factors by human colon cancer lines. Cancer Res. 46:1164–1169. 1986.
44	Anzano MA, Rieman D, Prichett W, Bowen-Pope DF and Greig R: Growth factor production by human colon carcinoma cell lines. Cancer Res. 49:2898–2904. 1989.